Patrick Joseph Igoe
Life Sciences Patent AttorneyIndependent IP Litigation Consultant
Patrick Joseph Igoe is a consultant and registered patent attorney in New York. His focus is patent issues throughout Life Sciences - for example, diagnostic/therapeutic assays; medical devices/imaging technologies; Rx antibiotics, biologics, drugs, and vaccines; and OTC medicines. His expertise includes active ongoing evaluations of now-current patent and/or FDA litigations. Mr. Igoe directly handles both typical patent areas and IP deals. He has completed numerous patent filings and deals, directed licensing campaigns, and drafted commercial/IP contracts. His expertise includes subjects such as antidepressants; small molecule organic chemistry; catalytic antibody prodrugs; drug-eluting stents; crop protection pesticides; cancer assays; animal vaccines; birth control implants; drug-eluting polymers; and stereochemistry. Mr. Igoe has served as in-house counsel at Bayer Diagnostics, Wyeth, and Igen. He holds a JD from Albany Law School and a BS in Chemistry/Math from Union College. (This is me - Update Profile)
| 2003 - present | Life Sciences Patent Attorney Independent IP Litigation Consultant |
|---|---|
| 2000 - 2003 | In-House Legal Counsel Bayer Diagnostics (now Siemens Medical Solutions Diagnostics [NYSE:SI]) |
| 1997 - 2000 | In-House Legal Counsel American Home Products (now Wyeth [NYSE:WYE]) |
| 1993 - 1997 | In-House Legal Counsel IGEN (now Roche) |
| 1992 - 1993 | Assistant Patent Examiner/GS13 level United States Patent And Trademark Office/Group Art Unit 1102/electrochemistry/classes 204 and 205 |
GLG Study Groups with Patrick Joseph Igoe(?)
| Study Group Name | Members |
|---|---|
| Generic Drug Economic Experts | 635 |
| Medical Device Patent Experts: Lawyers (US) | 78 |
| Biotechnology Patent Experts: Lawyers (US) | 100 |
| Medical Device Experts | 264 |
GLG NewsSM Analyses by Patrick Joseph Igoe(?)
* As noted in the Wall Street Journal article, Aricept® is a blockbuster drug for the treatment of Alzheimer's disease. And, as noted in Judge Ackerman's ruling, Aricept sales are a huge source of Eisai's revenue - "sales of Aricept® in the United States constitute 70% of Eisai’s...
(1) The US Court of Appeals for the Federal Circuit - in a complicated 22-page split Opinion earlier today Wed 19 Mar 2008 - provided Amgen another victory in its long patent battle(s) with Hoffmann-LaRoche. (2) Amgen's Aranesp® and EPOGEN® (each a prescription only product...
The at-risk product launch by [NasdaqGS:TEVA] Teva of generic equivalents to [NYSE:PFE] Pfizer's Neurontin® (gabapentin) might - and the emphasis is clearly on might - yet prove to be an expensive mistake by Teva. The recent Opinion by the United States Court of Appeals for the Federal Circuit...
In my prior Tue 31 Jul 2007 Analysis available here http://news.glgroup.com/CM/Analysis/PostDetail.aspx?pid=14722 I stated: The upcoming Altace ® Opinion will most likely fall in line with this noted trend. In other words, King Pharmaceutical [NYSE:KG]'s patent protection for Altace ® (ramipril)...
GLG InstituteSM Seminars with Patrick Joseph Igoe(?)
Recent Seminars
Request a project with Patrick Joseph Igoe
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms